The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 91 (high attention) · dilution pressure high · listing risk low · governance risk low · runway 1.0 mo · strongest signal: Equity line (Aug 13, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (atm program, convertible note, equity line, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 13, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-13 filing | 51 |
| Aug 13, 2026 | ▼ Offering (424B) | 424B5 prospectus supplement 2026-08-13; 0 prior 424B filings in 12m filing | 50 |
| Aug 13, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-08-13 filing | 38 |
| Aug 13, 2026 | ▼ ATM program | “atm” language in 424B5 (424B5) filed 2026-08-13 filing | 38 |
| Aug 10, 2026 | ▼ Equity line | “equity line” language in 8-K (8-K) filed 2026-08-10 filing | 45 |
| Aug 10, 2026 | ▼ Convertible note | “convertible note” language in 8-K (EX-4.1) filed 2026-08-10 filing | 39 |
| Aug 10, 2026 | ▼ ATM program | “atm” language in 8-K (8-K) filed 2026-08-10 filing | 38 |
| Aug 10, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-4.1) filed 2026-08-10 filing | 32 |
| Aug 10, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-10 (accepted 17:20 ET) filing | 27 |
| Aug 5, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-05 (accepted 17:00 ET) filing | 27 |
| Aug 5, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-08-05 (accepted 17:00 ET) filing | 25 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~1.0 months runway: liquidity $1,941,966 as of 2026-06-30, burn $22,554,163/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 48 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $1,941,966 vs current liabilities $10,410,693 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →